Aradigm to Present at Merriman Curhan Ford's 4th Annual Investor Summit on September 17.HAYWARD, Calif. -- Aradigm Corporation (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ARDM) today announced that President and Chief Executive Officer Igor Gonda, Ph.D. will present at the Merriman Curhan Ford 4th Annual Investor Summit on Monday, September 17, 2007, at 2:15 p.m. Pacific time. This event will be held at the Mark Hopkins InterContinental Hotel in San Francisco. More information about the conference can be found at: www.merrimanco.com Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Company's Web site for 14 days. About Aradigm Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis cystic fibrosis (sĭs`tĭk fībrō`sĭs), inherited disorder of the exocrine glands (see gland), affecting children and young people; median survival is 25 years in females and 30 years in males. , bronchiectasis bronchiectasis Abnormal expansion of bronchi in the lungs. It usually results when preexisting lung disease causes bronchial inflammation and obstruction. Bronchial wall fibres degenerate, and bronchi become dilated or paralyzed, preventing removal of secretions, which , pulmonary hypertension Pulmonary Hypertension Definition Pulmonary hypertension is a rare lung disorder characterized by increased pressure in the pulmonary artery. The pulmonary artery carries oxygen-poor blood from the lower chamber on the right side of the heart (right , inhalation anthrax inhalation anthrax Pulmonary anthrax, woolsorter's disease Pulmonology Occupational anthrax caused by inhalation of Brucella anthracis spores, affecting those exposed to aerosols during early processing of goat or other infected animal hair Clinical infections and smoking cessation. In addition, Aradigm's AERx[R] insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes type 2 diabetes n. See diabetes mellitus. . Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense. More information about Aradigm can be found at www.aradigm.com. Aradigm, AERx, and AERx Essence are registered trademarks and the Aradigm Logo is a trademark of Aradigm Corporation. SOURCE: Aradigm |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion